Table 2.

Probability of a Survival Benefit for Cisplatin-Based Adjuvant Chemotherapy for NSCLC Before and After Sequential Updating: Base Case And Sensitivity Analysis

5-Year Survival Benefit	Probability of Survival Benefit (%)			Updated Probability of Survival Benefit (%)
	Before IALT			After IALT			After IALT and JBR.10			After IALT, JBR.10, and ANITA
	Base Case	Expert	Uninformed	Base Case	Expert	Uninformed	Base Case	Expert	Uninformed	Base Case	Expert	Uninformed
Any benefit	48	43	35	86	85	61	89	89	88	89	89	88
Survival decrement	1.5	6.7	15.4	0.5	0.1	0.6	0	0	0	0	0	0
≥ 2% benefit	44	34	33	84	78	57	88	86	85	89	88	87
≥ 4% benefit	33	21	30	64	52	43	75	66	73	82	77	81
≥ 6% benefit	18	10	28	24	16	21	34	26	42	43	35	51

NOTE. The probability of each survival benefit level before the results of IALT (base case and sensitivity analysis), the updated probability of survival benefit after IALT, after sequentially updating with JBR.10, and after sequentially updating with ANITA is shown.

Abbreviations: NSCLC, non–small-cell lung cancer; IALT, International Adjuvant Lung Trial; ANITA, Adjuvant Navelbine International Trialist Association.